Context: Somatic mutations have been identified in more than half of aldosterone-producing adenomas (APAs) through mutation hotspot sequencing. The underlying pathogenesis of inappropriate aldosterone synthesis in the remaining population is still unknown.
CACNA1H (6) , and CLCN2 (7, 8) . Several studies have investigated the presence of the various aldosterone-driving mutations in APA. The largest mutation prevalence study to date was conducted by the European Network for the Study of Adrenal Tumors investigators. By sequencing directed at previously reported mutational hotspots and selected exons, Fernandes-Rosa et al. (9) assessed 474 APAs obtained through the European Network for the Study of Adrenal Tumors. This large, multicenter collaborative study identified somatic mutations in 54% of APAs, with KCNJ5 being the most frequently altered (9) . Although genetic causes have been identified in many APAs, the proportion of tumors without known mutations remains high (9) (10) (11) (12) (13) (14) . Furthermore, the prevalence of reported somatic mutations in APAs has varied by race. In particular, somatic KCNJ5 mutations are much more common in East Asian patients than in Europeans (12) (13) (14) . An important caveat to the somatic mutation prevalence studies just described is that nearly all assessed only hotspot regions or selected exons of the previously described genes.
The development of aldosterone synthase (CYP11B2)-specific antibodies has enabled the identification of aldosterone-producing cells in adrenal tissues. CYP11B2 immunohistochemistry (IHC) provides important insight into the histopathologic and functional landscape of PA (15) (16) (17) (18) (19) . Importantly, CYP11B2 IHC demonstrated that the aldosterone-producing source(s) may not always correspond with macroscopic adenomas (15, 18, 20) and that CYP11B2 expression may display distinct heterogeneity within a tumor (21) . Previous studies that focused on assessing the prevalence of somatic mutations in APAs sequenced tumor DNA without prior demonstration of CYP11B2 expression, raising the possibility of sequence analysis of nonfunctional or nonaldosterone-producing lesions. Hence, in the current study, we investigated the prevalence of somatic mutations in APAs using a CYP11B2 IHC-guided, comprehensive NGS approach targeting the entire coding regions of a panel of genes frequently mutated in APAs.
Materials and Methods

Patients
Eighty-five white American patients with adrenal tumor(s) who were diagnosed as having PA and who underwent adrenalectomy at the University of Michigan between 1995 and 2016 were studied. The patients were selected on the basis of the availability of formalin-fixed paraffin-embedded (FFPE) adrenal tissue blocks. Race was determined by self-identification as Caucasian or white. The clinical diagnosis of PA was made according to available institutional guidelines at the time or the Endocrine Society's clinical practice guideline (22) . Subtype classification was performed according to the results of crosssectional imaging (CT or MRI) and/or adrenal venous sampling. Sections from FFPE adrenal tissue blocks were used for IHC and genetic analyses. This study was approved by the institutional review board of the University of Michigan.
IHC
CYP11B2 IHC was performed as described previously (21) . Adrenocortical adenomas containing CYP11B2-expressing cells were considered APAs. To assess the tumor's capacity for cortisol production, IHC for 17a-hydroxylase/17,20 lyase (CYP17A1), an enzyme required for cortisol biosynthesis, was also examined. The following primary antibodies were used for IHC: CYP11B2 (Millipore, MABS1251, mouse monoclonal; RRID:AB_2650562) (23, 24) and CYP17A1 (LifeSpan Biosciences, LS-B14227, rabbit polyclonal; RRID:AB_2088387) (25) .
DNA isolation and comprehensive NGS
On the basis of the CYP11B2 IHC results, samples were obtained from APAs by scraping unstained FFPE sections guided by the CYP11B2 IHC slide using a scalpel under the Olympus SZ-40 microscope. DNA from five CYP11B2-negative tumors from five patients with PA were also isolated. These CYP11B2-negative tumors existed as dominant tumors in the adrenal containing small adjacent APAs. Genomic DNA was isolated from scraped FFPE tissue samples using the AllPrep DNA/RNA FFPE kit (Qiagen). For mutational analysis, multiplexed PCR-based NGS was performed using Ion Torrent AmpliSeq sequencing as described previously (Thermo Fisher Scientific) (21) . The panel for library construction contained amplicons targeting the full coding regions of aldosterone-driving genes (KCNJ5, ATP1A1, ATP2B3, CACNA1D, and CACNA1H), genes that are associated with other adrenal diseases (PRKACA, PRKAR1A, and ARMC5), and hotspots in the oncogenes GNAS and CTNNB1. For somatic mutation identification, data analysis was performed as described previously using validated pipelines (26) . High-confidence somatic mutations observed herein that were previously reported in APAs were considered somatic mutations after visual inspection of readlevel data. For high-confidence somatic mutations observed herein that were not previously reported as somatic mutations in APAs, we performed visual inspection of read-level data and confirmed somatic origin by performing NGS on adjacent normal tissue. Lastly, we also confirmed these previously unreported somatic mutations by Sanger sequencing (Supplemental Methods).
Results
Distribution of somatic mutation spectrum in white American APAs
According to CYP11B2 IHC, of 85 adrenals from patients with PA, 74 had a single APA and 1 had two APAs. Because of low DNA sample quality, one APA was excluded from further analysis, resulting in a total cohort of 75 APAs from 74 patients. Clinical characteristics of these patients are shown in Table 1 . Using our CYP11B2 IHC-guided NGS approach, we achieved an average depth of 1,8163 coverage across the 75 APAs, identifying somatic mutations in 66 of 75 APAs (88%). The most frequently altered aldosterone-driving gene was KCNJ5 (32 of 75; 43%), followed by CACNA1D (16 of 75; 21%), ATP1A1 (13 of 75; 17%), and ATP2B3 (3 of 75; 4%) (Supplemental Fig. 1 ). Most of the identified KCNJ5 mutations occurred at either p.G151R or p.L168R, known aldosterone-dysregulating mutational hotspots in APAs (2) ( Table 2 ). KCNJ5 somatic mutations were more commonly observed in APAs from women than in those from men (70% vs 24%, respectively; P , 0.001 by x 2 test), whereas CACNA1D and ATP1A1 somatic mutations were more frequently found in male patients (Supplemental Fig. 1 ). No ATP2B3 mutations were identified in women within this cohort. CTNNB1 mutations (both p.S45F) were found in two women. In five patients, IHC identified six CYP11B2-positive satellite tumors adjacent to a dominant CYP11B2-negative adrenocortical tumor (non-APA). The representative IHC images of these adrenals are shown in Fig. 1 . In all ancillary small APAs, mutations in aldosterone-driving genes were identified by NGS (KCNJ5 p.G151R in two, CACNA1D p.F747L in one, CACNA1D p.A998V in one, and CACNA1D p.V1151F in two), whereas no aldosterone-driving mutations were identified in any of the CYP11B2-negative adrenocortical tumors. Of note, all five CYP11B2-negative tumors showed positive expression for CYP17A1 by IHC; by NGS, three of them harbored somatic GNAS gain-of-function mutations (p.R201H) that have been reported in cortisol-producing adrenocortical adenomas (27, 28) .
Previously unreported somatic mutations in APAs
Of the mutations identified, five to our knowledge have not been previously reported, including two mutations in KCNJ5 (p.[F140L;G151R] and p.T149delinsTI), one in ATP1A1 (p.E960_L964delinsAV), one in ATP2B3 (p.V422_L425delinsIT), and one in CACNA1D (p.V259G in two APAs) ( Table 2) . In all cases, the mutations identified in APAs were not seen in matched, adjacent, normal adrenal tissue, confirming that the mutations were somatic. The NGS findings of these previously unreported mutations are summarized in Supplemental Table 1 . Importantly, Sanger sequencing further confirmed the mutations (Supplemental Fig. 2 ). Readlevel data of these mutations, including the in cis KCNJ5 p. Previous studies of genetic mutations in patients with unilateral PA have used tissue from macroscopically identified nodules (presumed to be APAs) and mutation hotspot-based or selected exon-based sequencing approaches. By utilizing our CYP11B2 IHC-guided, fullgene-based NGS approach, we identified somatic mutations in 88% of APAs, a much higher detection rate of somatic mutations in APAs than previously reported [54% in the study by Fernandes-Rosa et al. (9) ; P , 0.001 by x 2 test]. As previously published (18) and observed in 5 of 85 of our PA cases (Fig. 1) , some APAs can exist as satellite tumors adjacent to dominant CYP11B2-negative tumors. In addition, the landscape of unilateral PA is even more diverse and includes multiple microscopic aldosterone-producing cell clusters or areas of diffuse zona glomerulosa hyperplasia (17) . With this in mind, materials from a dominant CYP11B2-negative tumor could have been used in past studies for DNA sequencing, leading to reduced opportunity to identify somatic mutations in aldosterone-driver genes.
In this white American cohort, KCNJ5 was the most frequently mutated gene in APAs, which is consistent with findings of previous studies from Europe and East Asian countries (9, 12-14, 34, 35) . Similar to the previous studies in Europe (9, 36, 37 ) and a recent meta-analysis (38), KCNJ5 mutations were more frequently observed in women; 70% of APAs from women in our group harbored KCNJ5 mutations, suggesting a possible role for measurement of 18-oxocortisol for PA subtype classification in women. However, considering the relatively small sample size of our study, a multicenter study with a larger sample size using a CYP11B2 IHC-guided sequencing approach is required to better define the prevalence of somatic mutations in APAs and to avoid potential institutional and/or selection bias.
In the current study, five previously unreported somatic mutations were identified. A full functional analysis of these variants showing an effect on aldosterone production is clearly beyond the focus of our current study. However, we clearly identified these variants as somatic mutations by excluding their presence in the matched, adjacent, normal adrenal DNA, providing evidence for a likely causative involvement of the phenotype of the analyzed APAs. Furthermore, most novel variants carry features shared with well-described pathogenic variants in the respective genes. That said, functional characterization of these mutations, including electrophysiological analysis, will be required in future studies.
Previously unreported KCNJ5 somatic mutations include p.[F140L;G151R] and p.T149delinsTI. The KCNJ5 gene encodes the G protein-activated inward rectifier potassium channel 4 (GIRK4). The p.T149delinsTI mutation is located near the highly conserved glycine-thyrosine-glycine https://academic.oup.com/jcemmotif of the ion selectivity filter. Several mutations around these residues, including p.G151R mutation, have been shown to increase adrenal cell CYP11B2 transcription and enhance aldosterone production through cell membrane depolarization due to loss of ion selectivity of the channel (2, (39) (40) (41) (42) , supporting the pathologic role of the mutations identified in this study. The previously undescribed ATP1A1 p.E960_ L964delinsAV mutation locates at the transmembrane domain 9 of the a1 subunit of the Na + /K + -ATPase.
Several APA-related somatic mutations have been identified in the transmembrane domain 9 (4, 34). The E961 residue is thought to contribute to forming a third Na + -binding site and to have an important role in pump function (43, 44) . A somatic ATP1A1 mutation in APA involving this residue (p.E960_A963delinsS) was shown to cause inward leak currents in an electrophysiological study using Xenopus laevis oocytes (4). Most of the previously reported mutations in ATP2B3 have been identified in the transmembrane domain 4, where the ATP2B3 p.V422_L425delinsIT mutation locates. The transmembrane domain 4 of the pump is thought to be essential for the binding of Ca 2+ ions, and an in vitro study introducing the previously reported L425_V426del mutation into NCI-H295R cells demonstrated increased intracellular Ca 2+ activity and enhanced aldosterone production with increased CYP11B2 expression (45) . Lastly, a CACNA1D mutation, p.V259G, was recurrently identified in two APAs. Somatic mutations affecting the same residue (CACNA1D p.V259D) were previously reported in APAs and were functionally characterized as causing increased intracellular Ca 2+ concentration and elevated aldosterone production (4, 46) . The current study demonstrated that CYP11B2 IHCdirected tumor selection and a comprehensive, full coding sequence-based NGS approach results in a higher prevalence of somatic mutations than non-IHC-directed, hotspot/selected exon sequencing-based approaches. In agreement with previous studies (21, 37) , aldosterone-driving mutations were not found in CYP11B2-negative tumor samples. The heterogeneity of CYP11B2 expression patterns in adrenals from patients with PA has been documented, and this may help explain discrepancies between macroscopic-guided sequencing and the current study's CYP11B2-guided sequencing results. In summary, the consideration of CYP11B2 expression (by IHC or RNA analysis) and the use of comprehensive NGS-based approaches may more accurately determine the frequency and spectrum of aldosterone-driving gene mutations in APAs, maximizing the opportunity for clinical applications in patients with PA.
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